Sequans Communications SA ADR (SQNS) Reaches $4.46 After 9.00% Down Move, Rock Springs Capital Management LP Has Trimmed Therapeuticsmd (TXMD) Position By $400,000

May 31, 2017 - By marketbeat

The stock of Sequans Communications SA ADR (NYSE:SQNS) is a huge mover today! About 284,349 shares traded. Sequans Communications SA ADR (NYSE:SQNS) has risen 90.48% since May 31, 2016 and is uptrending. It has outperformed by 73.78% the S&P500.The move comes after 9 months negative chart setup for the $340.50 million company. It was reported on May, 31 by Barchart.com. We have $4.06 PT which if reached, will make NYSE:SQNS worth $30.65 million less.

Rock Springs Capital Management Lp decreased Therapeuticsmd Inc (TXMD) stake by 4.44% reported in 2016Q4 SEC filing. Rock Springs Capital Management Lp sold 80,000 shares as Therapeuticsmd Inc (TXMD)’s stock declined 24.96%. The Rock Springs Capital Management Lp holds 1.72M shares with $9.92 million value, down from 1.80M last quarter. Therapeuticsmd Inc now has $784.06 million valuation. The stock rose 3.78% or $0.14 reaching $3.98. About 381,941 shares traded. TherapeuticsMD Inc (NYSEMKT:TXMD) has declined 46.30% since May 31, 2016 and is downtrending. It has underperformed by 63.00% the S&P500.

Sequans Communications S.A. is a fabless designer, developer and supplier of fourth Generation long term evolution semiconductor solutions for wireless broadband applications, with a specific focus on the single-mode device market. The company has market cap of $340.50 million. The Company’s semiconductor solutions integrate baseband processor and radio frequency (RF) transceiver integrated circuits (ICs) along with its signal processing techniques, algorithms and software stacks. It currently has negative earnings. In the broadband data device market, its solutions serve as the wireless communications platform in devices, such as smartphones; Universal Serial Bus (USB) dongles; portable routers; embedded wireless modems for laptops, tablets, and other consumer multimedia devices; and customer-premises equipment, such as fixed wireless access modems, routers and residential gateways.

Analysts await Sequans Communications SA ADR (NYSE:SQNS) to report earnings on July, 27. They expect $-0.06 earnings per share, up 45.45% or $0.05 from last year’s $-0.11 per share. After $-0.06 actual earnings per share reported by Sequans Communications SA ADR for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Among 3 analysts covering Sequans Communications (NYSE:SQNS), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sequans Communications had 3 analyst reports since February 8, 2016 according to SRatingsIntel. The rating was initiated by B. Riley & Co with “Buy” on Friday, March 18. The stock of Sequans Communications SA ADR (NYSE:SQNS) earned “Buy” rating by Needham on Monday, February 8. The rating was initiated by Canaccord Genuity on Tuesday, May 17 with “Buy”.

Among 4 analysts covering TherapeuticsMD (NYSEMKT:TXMD), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TherapeuticsMD had 6 analyst reports since September 21, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Tuesday, November 22 by Oppenheimer. As per Monday, September 21, the company rating was maintained by Jefferies. Jefferies reinitiated it with “Buy” rating and $18 target in Tuesday, November 22 report. Jefferies maintained TherapeuticsMD Inc (NYSEMKT:TXMD) on Tuesday, December 8 with “Buy” rating. The company was maintained on Tuesday, December 8 by Stifel Nicolaus.

Rock Springs Capital Management Lp increased Radius Health Inc (NASDAQ:RDUS) stake by 18,250 shares to 910,250 valued at $34.62 million in 2016Q4. It also upped Exelixis Inc (NASDAQ:EXEL) stake by 50,000 shares and now owns 175,000 shares. Pra Health Sciences Inc was raised too.

Analysts await TherapeuticsMD Inc (NYSEMKT:TXMD) to report earnings on August, 3. They expect $-0.11 EPS, 0.00% or $0.00 from last year’s $-0.11 per share. After $-0.11 actual EPS reported by TherapeuticsMD Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Investors sentiment increased to 1.54 in 2016 Q4. Its up 0.22, from 1.32 in 2016Q3. It increased, as 15 investors sold TXMD shares while 35 reduced holdings. 31 funds opened positions while 46 raised stakes. 162.01 million shares or 5.89% more from 152.99 million shares in 2016Q3 were reported. Citadel owns 1.44 million shares or 0.01% of their US portfolio. Principal Group accumulated 20,893 shares. Heartland Advisors has invested 0.24% in TherapeuticsMD Inc (NYSEMKT:TXMD). Riggs Asset Managment Incorporated holds 10,000 shares or 0.03% of its portfolio. Moreover, Kistler has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD) for 1,000 shares. Ameritas Investment Prns Inc invested in 12,961 shares. Janney Montgomery Scott Limited Liability Co reported 31,158 shares. Menta Cap holds 68,785 shares or 0.03% of its portfolio. Guggenheim Ltd invested 0% in TherapeuticsMD Inc (NYSEMKT:TXMD). Everpoint Asset Mgmt Llc stated it has 0.01% in TherapeuticsMD Inc (NYSEMKT:TXMD). Massachusetts Services Ma has invested 0% of its portfolio in TherapeuticsMD Inc (NYSEMKT:TXMD). Sabby Mngmt Ltd Co holds 0.01% or 24,955 shares in its portfolio. Franklin has invested 0.03% in TherapeuticsMD Inc (NYSEMKT:TXMD). Susquehanna International Grp Llp has 0% invested in TherapeuticsMD Inc (NYSEMKT:TXMD). Prudential Fincl Inc holds 14,860 shares.